Andson Biotech

Executive Summary

Andson Biotech is a US-based biotechnology company specializing in innovative tools for mass spectrometry sample preparation. Founded in 2016 and headquartered in San Diego, the company's core technology, the DynaChip X1 platform, leverages proprietary microfluidics to automate buffer exchange and processing of complex biomolecules. By removing technical bottlenecks in analytical workflows, Andson aims to accelerate biotherapeutic discovery and development. The company operates in the drug delivery and small molecules categories, addressing a critical need for efficiency and reproducibility in biopharmaceutical analysis. As a private entity without disclosed funding or valuation, Andson's market traction remains nascent, but its focus on simplifying mass spectrometry sample prep positions it well in a growing segment of the life sciences tools market.

Upcoming Catalysts (preview)

• Q4 2026Commercial launch of DynaChip X1 platform70% success
• Q2 2027Strategic partnership with major biopharma for workflow integration50% success
• Q3 2026Series A funding round or grant announcement60% success